Literature DB >> 11424142

Candidate region for Gilles de la Tourette syndrome at 7q31.

P M Kroisel1, E Petek, W Emberger, C Windpassinger, W Wladika, K Wagner.   

Abstract

Gilles de la Tourette Syndrome (GTS) is a complex neuropsychiatric disorder characterized by motor and vocal tics. The cause of this syndrome is unknown, although based on family studies there is evidence of a strong genetic component. We report on a 13-year-old boy with GTS, minor physical anomalies, and a de novo partial duplication of chromosome 7q [dup(7)(q22.1-q31.1)]. The distal breakpoint in our patient is similar to the breakpoint of an apparently balanced familial translocation t(7;18) segregating with GTS. Together, these cases provide evidence that a gene located in the breakpoint region at 7q31 can be involved in the formation of GTS. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11424142     DOI: 10.1002/1096-8628(20010701)101:3<259::aid-ajmg1374>3.0.co;2-#

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  18 in total

Review 1.  The genetics of Tourette disorder.

Authors:  Matthew W State
Journal:  Curr Opin Genet Dev       Date:  2011-01-27       Impact factor: 5.578

2.  Translocation breakpoint in two unrelated Tourette syndrome cases, within a region previously linked to the disorder.

Authors:  Fiona C Crawford; Ghania Ait-Ghezala; Mark Morris; Maxine J Sutcliffe; Robert A Hauser; Archie A Silver; Michael J Mullan
Journal:  Hum Genet       Date:  2003-04-16       Impact factor: 4.132

3.  Indications of linkage and association of Gilles de la Tourette syndrome in two independent family samples: 17q25 is a putative susceptibility region.

Authors:  P Paschou; Y Feng; A J Pakstis; W C Speed; M M DeMille; J R Kidd; B Jaghori; R Kurlan; D L Pauls; P Sandor; C L Barr; K K Kidd
Journal:  Am J Hum Genet       Date:  2004-08-09       Impact factor: 11.025

Review 4.  The genetics of Tourette syndrome.

Authors:  Hao Deng; Kai Gao; Joseph Jankovic
Journal:  Nat Rev Neurol       Date:  2012-03-13       Impact factor: 42.937

5.  Genetic disruption of Met signaling impairs GABAergic striatal development and cognition.

Authors:  G J Martins; M Shahrokh; E M Powell
Journal:  Neuroscience       Date:  2010-12-31       Impact factor: 3.590

6.  Chromosomal rearrangements in Tourette syndrome: implications for identification of candidate susceptibility genes and review of the literature.

Authors:  Birgitte Bertelsen; Nanette Mol Debes; Lena E Hjermind; Liselotte Skov; Karen Brøndum-Nielsen; Zeynep Tümer
Journal:  Neurogenetics       Date:  2013-08-29       Impact factor: 2.660

7.  Molecular and genomic studies of IMMP2L and mutation screening in autism and Tourette syndrome.

Authors:  Erwin Petek; Thomas Schwarzbraun; Abdul Noor; Megha Patel; Kazuhiko Nakabayashi; Sanaa Choufani; Christian Windpassinger; Mara Stamenkovic; Mary M Robertson; Harald N Aschauer; Hugh M D Gurling; Peter M Kroisel; Klaus Wagner; Stephen W Scherer; John B Vincent
Journal:  Mol Genet Genomics       Date:  2006-10-17       Impact factor: 3.291

8.  Disruption of a novel gene (IMMP2L) by a breakpoint in 7q31 associated with Tourette syndrome.

Authors:  E Petek; C Windpassinger; J B Vincent; J Cheung; A P Boright; S W Scherer; P M Kroisel; K Wagner
Journal:  Am J Hum Genet       Date:  2001-03-09       Impact factor: 11.025

9.  Translocation breakpoint at 7q31 associated with tics: further evidence for IMMP2L as a candidate gene for Tourette syndrome.

Authors:  Chirag Patel; Lisa Cooper-Charles; Dominic J McMullan; Judith M Walker; Val Davison; Jenny Morton
Journal:  Eur J Hum Genet       Date:  2011-03-09       Impact factor: 4.246

10.  Intragenic deletions affecting two alternative transcripts of the IMMP2L gene in patients with Tourette syndrome.

Authors:  Birgitte Bertelsen; Linea Melchior; Lars R Jensen; Camilla Groth; Birte Glenthøj; Renata Rizzo; Nanette Mol Debes; Liselotte Skov; Karen Brøndum-Nielsen; Peristera Paschou; Asli Silahtaroglu; Zeynep Tümer
Journal:  Eur J Hum Genet       Date:  2014-02-19       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.